Get the Stockscreener App
2.99
0.33%
-0.010
After Hours:
3.00
0.010
+0.33%
Humacyte Inc Stock (HUMA) Latest News
Humacyte’s Symvess: A Transformative Solution in Vascular Trauma Care with Strong Market Potential - TipRanks
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics - The Manila Times
Humacyte Announces Economic Value of Symvess in Budget Impact Model Publication - Nasdaq
New Study: Humacyte's Symvess Cuts Trauma Center Costs by $33,000 Per Patient - StockTitan
Humacyte’s SYMVESS Launch and Strategic Positioning Drive Buy Rating - TipRanks
Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital - Defense World
Rhumbline Advisers Acquires 5,005 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Benchmark maintains Humacyte stock Buy rating, $17 target - Investing.com India
Benchmark maintains Humacyte stock Buy rating, $17 target By Investing.com - Investing.com South Africa
Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Average Target Price from Analysts - Defense World
Humacyte Partners With Trestle Biotherapeutics on Bioengineered Kidney Research -March 06, 2025 at 09:16 am EST - Marketscreener.com
Humacyte, Trestle Biotherapeutics announce research collaboration - TipRanks
Can This Groundbreaking Biotech Partnership Solve the Kidney Transplant Crisis? - StockTitan
Trestle Bio Announces Research Collaboration with Humacyte - The Bakersfield Californian
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 - The Manila Times
Will Humacyte's First-in-Class Bioengineered Vessel Transform Trauma Care? Investors to Get Answers - StockTitan
Atria Wealth Solutions Inc. Makes New Investment in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Buy Rating for Humacyte Driven by Symvess Launch and Economic Advantages - TipRanks
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Shareholder Rights Advocates at Levi & Korsinsky Investigate Humacyte, Inc. (HUMA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know - MSN
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Humacyte's Presentation at TD Cowen Conference Reveal New Bioengineered Tissue Breakthroughs? - StockTitan
Humacyte Shares Rise After Receiving US Patent for Bioreactor Manufacturing System - Marketscreener.com
Humacyte secures patent for bioreactor system until 2040 By Investing.com - Investing.com South Africa
Humacyte secures patent for bioreactor system until 2040 - Investing.com India
Humacyte announces issuance of U.S. patent covering Symvess manufacturing - TipRanks
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues - The Manila Times
Can Humacyte's New Patent Transform Trauma Care? FDA-Approved Tissue Tech Now Protected Until 2040 - StockTitan
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineHUMA - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Stockholders to Reach Out - ACCESS Newswire
Promising Commercial Launch and Strategic Positioning Drive Buy Rating for Humacyte - TipRanks
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Humacyte announces commercial launch of Symvess™ (acellular tissue engineered vessel-tyod) for extremity vascular trauma - PharmaLive
FDA approves Humacyte's Symvess for vascular injuries By Investing.com - Investing.com South Africa
Humacyte announces commercial launch of Symvess - TipRanks
FDA approves Humacyte’s Symvess for vascular injuries - Investing.com India
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma - The Manila Times
FDA approves Humacyte's Symvess for vascular injuries - Investing.com
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity - EIN News
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - ACCESS Newswire
Lost Money on Humacyte, Inc. (HUMA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven? - Yahoo Finance UK
Humacyte stock rallies 19% on FDA RMAT designation - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Humacyte, Inc. to Contact the Firm Today! - ACCESS Newswire
Humacyte moves to test bioengineered vessel in heart surgery - MSN
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights - MSN
LJI Wealth Management LLC Purchases Shares of 185,000 Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
North Carolina biotech weighs demand as breakthrough treatment hits market - The Business Journals
Trilogy Capital Inc. Buys New Holdings in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know - MSN
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bullish Humacyte Insiders Loaded Up On US$803.3k Of Stock - Simply Wall St
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):